Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 9034-9034 ◽  
Author(s):  
Paolo Antonio Ascierto ◽  
David R. Minor ◽  
Antoni Ribas ◽  
Celeste Lebbe ◽  
Anne O'Hagan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Metastatic Melanoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Previously Treated

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients

2009 ◽  
Vol 19 (4) ◽  
pp. 238-242 ◽  
Author(s):  
Jade Homsi ◽  
Agop Y. Bedikian ◽  
Kevin B. Kim ◽  
Nicholas E. Papadopoulos ◽  
Wen-Jen Hwu ◽  
...  
Keyword(s):  
Docosahexaenoic Acid ◽  
Metastatic Melanoma ◽  
Phase 2 ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Melanoma Patients

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

2017 ◽  
Vol 1 ◽  
pp. s95 ◽  
Author(s):  
Dee Anna Glaser ◽  
Adelaide A Hebert ◽  
Alexander Nast ◽  
William P Werschler ◽  
Stephen Shideler ◽  
...  
Keyword(s):  
Axillary Hyperhidrosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Abstract Not AvailableDisclosure: Study supported by Dermira.

Sign in / Sign up

Export Citation Format

Share Document